Drugs / YH001
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT05176509 | Apr 2022 → Aug 2023 | cancer | Eucure (Beijing) Biopharma Co., Ltd | Completed | No outcome recorded |
| Phase 1 | NCT05169697 | Feb 2022 → Jul 2023 | neoplasm | Eucure (Beijing) Biopharma Co., Ltd | Completed | No outcome recorded |
| Phase 1 | NCT04699929 | Jan 2021 → Oct 2022 | cancer | Eucure (Beijing) Biopharma Co., Ltd | Completed | No outcome recorded |
| Phase 1 | NCT04357756 | Apr 2020 → Oct 2022 | neoplasm | Eucure (Beijing) Biopharma Co., Ltd | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05448820 | Nov 2022 → Nov 2023 | soft tissue sarcoma | Tracon Pharmaceuticals Inc. | Unknown | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05212922 | Jun 2023 → Dec 2024 | hepatocellular carcinoma, non-small cell lung carcinoma | Eucure (Beijing) Biopharma Co., Ltd | Withdrawn | No outcome recorded Stop: Business |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | YH001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04699929 ↗ |
| Route | Intravenous | “YH001 will be administered intravenously every three weeks (Q3W) for 15 weeks (5 cycles) at doses of Dose A, Dose B, Dose C, Dose D, Dose E, Dose F and Dose G.” NCT04357756 ↗ |
| Target | CTLA4 | “Anti-CTLA4 antibody” NCT05448820 ↗ |